A Phase 1/2 interventional study of Sham iTBS and TMS in Major Depression and Healthy Participants, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Mclean Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cycloserine in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Cycloserine · Depressive Disorder, Major.
Among the 10 studies testing cycloserine in Depressive Disorder, Major, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 9th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 10 studies testing cycloserine in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Cycloserine: first FDA approval 1964 (SEROMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 43 across the 10 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 7 most frequent:
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
32 studies in Depressive Disorder, Major by Mclean Hospital: 7 open now, 7 under way, none of them phase 3. Of 24 finished, 12 (50%) have results posted.
Among the 32 studies in Depressive Disorder, Major by Mclean Hospital, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, and was the 30th registered.
Mclean Hospital’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cycloserine in Depressive Disorder, Major, from their registry updates:
Among Mclean Hospital’s 32 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
Many people with depression do not get better with standard treatments like medications or talk therapy. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment that uses magnetic pulses to stimulate areas of the brain involved in depression. One form of TMS called intermittent theta burst stimulation (iTBS) is FDA-cleared for depression and takes only 3 minutes to deliver. However, about one-third of patients do not respond to iTBS, and another one-third do not reach full remission. Improving iTBS requires a better understanding of how it works in the brain.
iTBS is thought to work by strengthening connections between brain cells, a process called synaptic plasticity. This process depends on a type of brain receptor called the NMDA receptor. Most of what researchers know about how iTBS affects these connections comes from studies of healthy people. It is not known whether iTBS works the same way in the prefrontal cortex - the brain region targeted during depression treatment - or in people who actually have depression.
This study has two phases.
In Phase 1, both healthy volunteers and people with depression will complete 4 research visits to test how iTBS changes brain activity in the prefrontal cortex and whether medications that increase or decrease NMDA receptor activity change those effects. Each visit involves active or sham (inactive) iTBS combined with one of three study medications: a placebo (inactive pill), d-cycloserine (a medication that increases NMDA receptor activity), or dextromethorphan (a medication that decreases NMDA receptor activity). Brain activity is measured before and after each TMS session using electroencephalography (EEG), a painless test that records electrical signals from the scalp through a cap placed on the head. All participants also complete a brain MRI before beginning study visits for targeting purposes.
In Phase 2, participants with depression will be offered a standard clinical course of 30 daily iTBS sessions (Monday through Friday over 6 weeks). Each session is combined with one blinded study medication (placebo, d-cycloserine, or dextromethorphan) taken daily. Brain activity measurements and standard depression and anxiety questionnaires are collected weekly throughout this phase to track how the brain changes over the course of treatment and whether those changes relate to improvements in symptoms.
Together, the two phases of this study aim to identify the brain mechanism by which iTBS works in people with depression. This knowledge could lead to more effective TMS treatments for people who have not responded to medications or other therapies.
Major depressive disorder (MDD) affects an estimated 280 million people worldwide. Approximately one-third of patients do not respond adequately to first-line treatments, a population referred to as having treatment-resistant depression (TRD). Intermittent theta burst stimulation (iTBS) is an FDA-cleared form of repetitive transcranial magnetic stimulation (rTMS) for TRD, but roughly one-third of TRD patients do not respond and another one-third do not achieve full remission. Progress in improving iTBS outcomes is most likely to come from a better understanding of its underlying mechanism of action.
iTBS is hypothesized to produce clinical effects through long-term potentiation (LTP), a process by which repeated stimulation strengthens synaptic connections between neurons. LTP depends critically on N-methyl-D-aspartate receptors (NMDARs). Evidence for this mechanism comes primarily from animal studies and from studies of the motor cortex in healthy human volunteers, where cortical excitability changes can be measured using motor-evoked potentials (MEPs) detected by electromyography. These studies have demonstrated that high-frequency rTMS produces LTP-like effects that are enhanced by NMDAR agonism and blocked by NMDAR antagonism.
However, the relevance of motor cortex findings to the dorsolateral prefrontal cortex (dlPFC) - the clinical target for depression treatment - has not been directly tested. The motor cortex and dlPFC differ substantially in anatomy and interindividual variability. Depression itself is associated with reduced synaptic plasticity, as evidenced by neuropsychological, structural, and molecular findings including reduced expression of NMDAR subunits and synapse-related genes in postmortem prefrontal tissue. Whether LTP-like mechanisms established in the healthy motor cortex translate to the depressed dlPFC cannot be assumed.
The principal investigator's laboratory has produced relevant foundational work. Prior studies demonstrated that the NMDAR partial agonist d-cycloserine (DCS) enhances rTMS-induced LTP-like plasticity in the healthy motor cortex, and that the NMDAR antagonist dextromethorphan (DXM) blocks these effects. A separate randomized clinical trial found that augmenting iTBS with DCS more than doubled remission rates in MDD relative to iTBS plus placebo. A motor cortex study further found that DCS normalized iTBS-induced plasticity in depressed patients, who otherwise showed blunted responses relative to healthy controls, suggesting a plasticity deficit in depression that NMDAR agonism can partially rescue.
TMS-EEG now allows cortical excitability to be measured outside the motor cortex. TMS-evoked potentials (TEPs) are scalp-recorded electrical responses to individual TMS pulses, reflecting summated excitatory and inhibitory postsynaptic potentials from stimulated neuronal populations. Characteristic peaks are named by polarity and latency: positive peaks (P30, P60) are thought to reflect glutamatergic excitatory transmission, while negative peaks (N45, N100) reflect GABAergic inhibitory tone. The P30 peak is the primary outcome measure for this study based on its high correlation with MEP amplitude, its sensitivity to iTBS, and its established reduction by AMPA receptor blockade, consistent with the AMPA receptor upregulation that characterizes LTP. No prior study has combined receptor-modulating pharmacology with rTMS to directly test the synaptic mechanism of iTBS in the dlPFC.
This is a two-phase study. Phase 1 is a within-subject crossover design in both healthy volunteers and participants with MDD, in which each participant completes 4 visits receiving different combinations of active or sham iTBS and oral study medication (placebo, DCS 100 mg, or DXM 150 mg) in randomized counterbalanced order, separated by at least one week. TMS-EEG is used to measure dlPFC excitability before drug administration, after drug administration but before iTBS, and immediately after iTBS. This phase tests whether NMDAR activity is necessary and sufficient for iTBS-induced plasticity in the dlPFC, and compares plasticity responses between healthy and depressed participants.
Phase 2 is a parallel-group design restricted to MDD participants who completed Phase 1, in which participants receive 30 daily weekday iTBS sessions combined with once-daily administration of a single blinded study drug (placebo, DCS 100 mg, or DXM 150 mg). Weekly TMS-EEG assessments track longitudinal change in dlPFC excitability over the treatment course. Phase 2 is considered exploratory.
DCS at 100 mg acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It reaches near-peak plasma levels within 1-2 hours of oral administration. DXM at 150 mg produces brain concentrations consistent with NMDA receptor blockade in vitro and has been shown in prior studies to block the plasticity after-effects of iTBS, cTBS, tDCS, and other rTMS paradigms. All study medications are dispensed by the McLean Research Pharmacy in blinded, identical capsules.
TMS is delivered using the Nexstim NBS-6 Research System and/or the MagVenture MagPro X100, both FDA-cleared devices with integrated EEG, EMG, and real-time neuronavigation. Individual structural MRI obtained prior to study visits is used for neuronavigation-guided dlPFC targeting and EEG source localization. Resting-state fMRI is collected to enable exploratory post-hoc comparisons of functional connectivity with TEP-measured plasticity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo TMS and placebo drug
Device: Sham iTBS · Drug: Placebo
Active TMS and placebo drug
Device: TMS · Drug: Placebo
Active TMS and active medication
Device: TMS · Drug: D-cycloserine
Active TMS and active medication
Device: TMS · Drug: Dextromethophan
ham intermittent theta burst stimulation delivered to the left dorsolateral prefrontal cortex using a sham coil identical in appearance to the active coil. No active magnetic stimulation is delivered. Used to control for the sensory experience of TMS.
Also known as: Transcranial magnetic stimulation, sham
Active intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex combined with oral placebo. iTBS consists of 50 Hz triplets delivered in 2-second bursts at 5 Hz, totaling 600 pulses per session over approximately 3 minutes, delivered using a figure-of-8 coil with real-time neuronavigation at an intensity set relative to each participant's resting motor threshold.
Also known as: transcranial magnetic stimulation, iTBS, intermittent theta-burst stimulation
D-cycloserine at 100 mg acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It is administered orally approximately 2 hours before iTBS to coincide with near-peak plasma concentration. Compounded as 100 mg capsules.
Also known as: DCS
Dextromethorphan at 150 mg acts as an NMDA receptor antagonist, blocking NMDAR-mediated synaptic transmission at brain concentrations consistent with in vitro receptor blockade. Administered orally approximately 2 hours before iTBS.
Also known as: DMO, DXM
Microcrystalline cellulose capsule identical to the drug capsules, administered 2 hours prior to iTBS treatment.
Also known as: PBO
P30 TMS-Evoked Potential (TEP) Amplitude
Change in P30 peak amplitude measured by TMS-EEG before and after a single iTBS session. The P30 is a positive deflection occurring approximately 30 milliseconds after a TMS pulse, reflecting glutamatergic excitatory synaptic transmission. Change in P30 amplitude serves as an index of iTBS-induced LTP-like plasticity in the left dorsolateral prefrontal cortex. Comparisons will be made across drug conditions (placebo, d-cycloserine, dextromethorphan), between TMS conditions (active vs. sham), and between participant groups (MDD vs. healthy controls).
Time frame: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks
Additional TEP Component Amplitudes
Change in amplitude of additional TEP peaks (N45, P60, and N100) measured before and after iTBS. P60 reflects mixed glutamatergic contributions, N45 reflects GABA-A receptor-mediated inhibitory tone, and N100 reflects GABA-B receptor-mediated inhibitory tone. These components are examined as exploratory markers of drug- and iTBS-induced changes in excitatory and inhibitory synaptic transmission in the dlPFC.
Time frame: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks
16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16)
Self report measure of depressive symptoms. Score range: 0-27. Higher scores indicate more severe symptoms.
Time frame: From enrollment to the end of treatment at 6 weeks
Patient Health Questionnaire-9 (PHQ-9)
Self report measure of depressive symptoms. Score range: 0-27. Higher scores indicate more severe symptoms.
Time frame: From enrollment to the end of treatment at 6 weeks
7-item Generalized Anxiety Disorder scale (GAD-7)
Self report measure of anxiety symptoms. Score range: 0-21. Higher scores indicate more severe symptoms.
Time frame: From enrollment to the end of treatment at 6 weeks
24-item Behavior and Symptom Identification Scale (BASIS-24)
Self report measure of mental health and functional difficulties. Range: 0-96. Higher scores indicate more severe symptoms.
Time frame: From enrollment to the end of treatment at 6 weeks
Plan to share: Yes — De-identified individual participant data will be shared through the National Institute of Mental Health Data Archive (NDA) in accordance with NIMH data sharing expectations. Data to be shared will include demographic information, clinical scale scores, and TMS-EEG outcome data. Data will be submitted to the NDA following standard de-identification procedures and will be made available to qualified researchers through the NDA data access request process.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Data will be submitted to the NDA within 1 year of primary study completion or upon publication of primary results, whichever comes first.
Access criteria: Data will be accessible to qualified researchers through the NIMH Data Archive data access request process.
Data sharing details ↗ · nda.nih.gov
Started Oct 2026 (actual). Primary completion is estimated for Dec 2030, 50 months after the start.
Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's planned 50 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cycloserine · Dextromethorphan